<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121173</url>
  </required_header>
  <id_info>
    <org_study_id>J0323 CDR0000439494</org_study_id>
    <secondary_id>R21CA105696</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0323</secondary_id>
    <secondary_id>JHOC-03-05-06-02</secondary_id>
    <nct_id>NCT00121173</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia</brief_title>
  <official_title>A Phase I/II Clinical Trial of pNGVL4a-Sig/E7 (Detox)/HSP70 for the Treatment of Patients With HPV 16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from protein and DNA may help the body build an effective immune
      response to kill abnormal cells in the cervix. The use of vaccine therapy may prevent
      cervical cancer.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy
      and to see how well it works in preventing cervical cancer in patients with cervical
      intraepithelial neoplasia and human papillomavirus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility and toxicity of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine in
           preventing cervical cancer in patients with human papillomavirus (HPV)-16-positive grade
           2 or 3 cervical intraepithelial neoplasia.

        -  Determine the effect of this vaccine on the histology of cervical tissue specimens from
           these patients.

      Secondary

        -  Determine changes in lesion size and HPV viral load in patients treated with this
           vaccine.

        -  Determine the cellular, humoral, and local tissue immune responses in patients treated
           with this vaccine.

        -  Correlate measures of immune response with clinical response in patients treated with
           this vaccine.

        -  Correlate measures of immune response in patients treated with this vaccine with those
           observed in the preclinical model.

      OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

        -  Phase I: Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine subcutaneously once in
           weeks 0, 4, and 8 in the absence of disease progression or unacceptable toxicity.
           Patients undergo colposcopy in week 8, 15 and 19 and a therapeutic loop electrosurgical
           excision procedure (LEEP) in week 15.

      Cohorts of patients receive escalating doses of vaccine until the safest dose is determined.

        -  Phase II: Patients receive vaccine as in phase I but at the safest dose determined in
           phase I. Patients also undergo colposcopy and LEEP as in phase I.

      After completion of the study treatment, patients are followed annually for 15 years.

      PROJECTED ACCRUAL: Approximately 150 patients (approximately 12 will be treated in phase I
      and 25 will be treated in phase II) will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Toxicity</measure>
    <time_frame>for the duration of the study, and whenever possible, for an additional 5 years</time_frame>
    <description>Number of participants with serious adverse events (SAE) according to CTCAE 3.0 grading.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>for the duration of the study, and whenever possible, for an additional 5 years</time_frame>
    <description>The efficacy of pNGVL4a-SigE7(detox)HSP70 DNA vaccine, administered intra-muscularly. This is reported as number of participants with histologic regression of CIN2/3 to CIN1 or less by colposcopically-directed biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regression of CIN3 Lesions</measure>
    <time_frame>15 weeks</time_frame>
    <description>Number of participants with absence of CIN3 lesions at week 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With T-cell Immune Responses in the Blood</measure>
    <time_frame>41 weeks</time_frame>
    <description>Systemic T-cell response as measured by Î³-INF enzyme-linked immunospot assays (ELISpot)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Correlated Measures of Immune Response With Clinical Response</measure>
    <time_frame>9 months</time_frame>
    <description>Number of participants whose t-cell immune responses correlated with histologic regression of disease or viral clearance of HPV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Correlated Measures of Immune Responses With the Preclinical Model</measure>
    <time_frame>9 months</time_frame>
    <description>Number of participants whose T-cell immune responses correlated with the immune responses observed in the preclinical model</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals.
Genetic (recombinant DNA vaccine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</intervention_name>
    <description>recombinant DNA vaccine</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed cervical intraepithelial neoplasia (CIN2/3)

          -  Human papillomavirus-16-positive disease

        PATIENT CHARACTERISTICS:

        - Age: &gt; 18

        Other

          -  Not pregnant

          -  Immunocompetent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L. Trimble, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clincancerres.aacrjournals.org/content/15/1/361.long</url>
    <description>Publication of study results in Clin Cancer Res</description>
  </link>
  <results_reference>
    <citation>Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009 Jan 1;15(1):361-7. doi: 10.1158/1078-0432.CCR-08-1725.</citation>
    <PMID>19118066</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 19, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>June 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2018</results_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>cervical intraepithelial neoplasia grade 2</keyword>
  <keyword>cervical intraepithelial neoplasia grade 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose</title>
          <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
        <group group_id="P2">
          <title>Intermediate Dose</title>
          <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
        <group group_id="P3">
          <title>High Dose</title>
          <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose</title>
          <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
        <group group_id="B2">
          <title>Intermediate Dose</title>
          <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
        <group group_id="B3">
          <title>High Dose</title>
          <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Participants age 18 and older</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Participants ages 18 and older</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="18" upper_limit="36"/>
                    <measurement group_id="B2" value="29" lower_limit="20" upper_limit="46"/>
                    <measurement group_id="B3" value="30.3" lower_limit="20" upper_limit="45"/>
                    <measurement group_id="B4" value="28.4" lower_limit="18" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Toxicity</title>
        <description>Number of participants with serious adverse events (SAE) according to CTCAE 3.0 grading.</description>
        <time_frame>for the duration of the study, and whenever possible, for an additional 5 years</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Toxicity</title>
          <description>Number of participants with serious adverse events (SAE) according to CTCAE 3.0 grading.</description>
          <population>per protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy</title>
        <description>The efficacy of pNGVL4a-SigE7(detox)HSP70 DNA vaccine, administered intra-muscularly. This is reported as number of participants with histologic regression of CIN2/3 to CIN1 or less by colposcopically-directed biopsy.</description>
        <time_frame>for the duration of the study, and whenever possible, for an additional 5 years</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy</title>
          <description>The efficacy of pNGVL4a-SigE7(detox)HSP70 DNA vaccine, administered intra-muscularly. This is reported as number of participants with histologic regression of CIN2/3 to CIN1 or less by colposcopically-directed biopsy.</description>
          <population>per protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regression of CIN3 Lesions</title>
        <description>Number of participants with absence of CIN3 lesions at week 15</description>
        <time_frame>15 weeks</time_frame>
        <population>per protocol; participants who had no CIN3 lesions assessed by colposcopy and biopsy(ies) at the week 15 visit</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals.
Genetic (recombinant DNA vaccine)
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine: recombinant DNA vaccine</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine: recombinant DNA vaccine</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine: recombinant DNA vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Regression of CIN3 Lesions</title>
          <description>Number of participants with absence of CIN3 lesions at week 15</description>
          <population>per protocol; participants who had no CIN3 lesions assessed by colposcopy and biopsy(ies) at the week 15 visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With T-cell Immune Responses in the Blood</title>
        <description>Systemic T-cell response as measured by Î³-INF enzyme-linked immunospot assays (ELISpot)</description>
        <time_frame>41 weeks</time_frame>
        <population>all patients who completed all 3 vaccinations</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With T-cell Immune Responses in the Blood</title>
          <description>Systemic T-cell response as measured by Î³-INF enzyme-linked immunospot assays (ELISpot)</description>
          <population>all patients who completed all 3 vaccinations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Correlated Measures of Immune Response With Clinical Response</title>
        <description>Number of participants whose t-cell immune responses correlated with histologic regression of disease or viral clearance of HPV</description>
        <time_frame>9 months</time_frame>
        <population>All participants who received all 3 vaccinations</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Correlated Measures of Immune Response With Clinical Response</title>
          <description>Number of participants whose t-cell immune responses correlated with histologic regression of disease or viral clearance of HPV</description>
          <population>All participants who received all 3 vaccinations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Correlated Measures of Immune Responses With the Preclinical Model</title>
        <description>Number of participants whose T-cell immune responses correlated with the immune responses observed in the preclinical model</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Dose</title>
            <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Correlated Measures of Immune Responses With the Preclinical Model</title>
          <description>Number of participants whose T-cell immune responses correlated with the immune responses observed in the preclinical model</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>19 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose</title>
          <description>3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
        <group group_id="E2">
          <title>Intermediate Dose</title>
          <description>3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
        <group group_id="E3">
          <title>High Dose</title>
          <description>3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/tiredness, flu-like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was completed, as planned.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cornelia L. Trimble, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-502-0512</phone>
      <email>ctrimbl@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

